Stay updated on FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial page.

Latest updates to the FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedGastric cancer added as a related topic/keyword and Genetic and Rare Diseases Information Center resources linked; the page revision updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedRevision label on the page updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check27 days agoChange DetectedThe page adds a 'Show glossary' option and updates QC metadata to 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', while removing the older entries 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.SummaryDifference0.1%

- Check41 days agoChange DetectedThe page footer now shows Revision: v3.3.4, replacing the previous Revision: v3.3.3.SummaryDifference0.0%

- Check62 days agoChange DetectedNew location entries were added for Florida, New York, Rio Grande do Norte, Region Met, Baden-Wurttemberg, Lower Saxony, and Saxony, while corresponding location entries were removed. The page revision was updated from v3.3.2 to v3.3.3.SummaryDifference0.5%

- Check91 days agoChange DetectedThe page shows a new site revision tag Revision: v3.3.2 replacing the previous v3.2.0; this appears to be a backend/UI version update with no visible changes to the study content or structure. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial page.